Nano X Imaging (NNOX)
Market Price (3/17/2026): $2.57 | Market Cap: $165.3 MilSector: Health Care | Industry: Life Sciences Tools & Services
Nano X Imaging (NNOX)
Market Price (3/17/2026): $2.57Market Cap: $165.3 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% | Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -131% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -470% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.88, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, and AI in Healthcare Management. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -333%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -368% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% | ||
| Short seller report | ||
| Key risksNNOX key risks include [1] a history of substantial financial losses requiring additional financing, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -103%, 3Y Excs Rtn is -131% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 13.88, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -58 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -470% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 39% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -333%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -368% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% |
| Short seller report |
| Key risksNNOX key risks include [1] a history of substantial financial losses requiring additional financing, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nano X Imaging (NNOX) stock has lost about 40% since 11/30/2025 because of the following key factors:
1. Analyst price target significantly reduced.
An analyst at D. Boral Capital lowered the price target for Nano X Imaging (NNOX) from $8.00 to $5.00 in February 2026, representing a 37.5% decrease.
2. Persistent financial losses and cash burn.
Nano X Imaging reported a GAAP net loss of $13.7 million on $3.4 million revenue for Q3 2025, with continued gross losses on imaging system and AI revenues. The company also demonstrated an operating cash burn of $30.4 million, contributing to a decline in cash reserves.
Show more
1. Analyst price target significantly reduced.
An analyst at D. Boral Capital lowered the price target for Nano X Imaging (NNOX) from $8.00 to $5.00 in February 2026, representing a 37.5% decrease.
2. Persistent financial losses and cash burn.
Nano X Imaging reported a GAAP net loss of $13.7 million on $3.4 million revenue for Q3 2025, with continued gross losses on imaging system and AI revenues. The company also demonstrated an operating cash burn of $30.4 million, contributing to a decline in cash reserves.
Show more
Stock Movement Drivers
Fundamental Drivers
The -42.2% change in NNOX stock from 11/30/2025 to 3/16/2026 was primarily driven by a -42.2% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.48 | 2.59 | -42.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 12 | 12 | 0.0% |
| P/S Multiple | 23.4 | 13.5 | -42.2% |
| Shares Outstanding (Mil) | 64 | 64 | 0.0% |
| Cumulative Contribution | -42.2% |
Market Drivers
11/30/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NNOX | -42.2% | |
| Market (SPY) | -2.1% | 38.2% |
| Sector (XLV) | -4.2% | -1.9% |
Fundamental Drivers
The -33.1% change in NNOX stock from 8/31/2025 to 3/16/2026 was primarily driven by a -34.9% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.87 | 2.59 | -33.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 12 | 12 | 3.5% |
| P/S Multiple | 20.8 | 13.5 | -34.9% |
| Shares Outstanding (Mil) | 64 | 64 | -0.6% |
| Cumulative Contribution | -33.1% |
Market Drivers
8/31/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NNOX | -33.1% | |
| Market (SPY) | 4.0% | 27.0% |
| Sector (XLV) | 10.4% | 22.6% |
Fundamental Drivers
The -58.2% change in NNOX stock from 2/28/2025 to 3/16/2026 was primarily driven by a -60.1% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.19 | 2.59 | -58.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11 | 12 | 15.2% |
| P/S Multiple | 34.0 | 13.5 | -60.1% |
| Shares Outstanding (Mil) | 59 | 64 | -8.9% |
| Cumulative Contribution | -58.2% |
Market Drivers
2/28/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NNOX | -58.2% | |
| Market (SPY) | 13.6% | 41.0% |
| Sector (XLV) | 2.7% | 31.0% |
Fundamental Drivers
The -64.5% change in NNOX stock from 2/28/2023 to 3/16/2026 was primarily driven by a -72.5% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.29 | 2.59 | -64.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 12 | 58.7% |
| P/S Multiple | 49.2 | 13.5 | -72.5% |
| Shares Outstanding (Mil) | 52 | 64 | -18.7% |
| Cumulative Contribution | -64.5% |
Market Drivers
2/28/2023 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NNOX | -64.5% | |
| Market (SPY) | 75.1% | 28.3% |
| Sector (XLV) | 24.3% | 20.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NNOX Return | -68% | -49% | -14% | 13% | -61% | -10% | -94% |
| Peers Return | 20% | -35% | 11% | 53% | 2% | -7% | 27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -3% | 77% |
Monthly Win Rates [3] | |||||||
| NNOX Win Rate | 25% | 50% | 33% | 33% | 42% | 33% | |
| Peers Win Rate | 56% | 37% | 57% | 48% | 52% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| NNOX Max Drawdown | -68% | -55% | -33% | -16% | -61% | -24% | |
| Peers Max Drawdown | -24% | -44% | -21% | -19% | -39% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GEHC, HOLX, RDNT, BFLY, VREX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/16/2026 (YTD)
How Low Can It Go
| Event | NNOX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.4% | -25.4% |
| % Gain to Breakeven | 1698.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -63.4% | -33.9% |
| % Gain to Breakeven | 172.9% | 51.3% |
| Time to Breakeven | 113 days | 148 days |
Compare to GEHC, HOLX, RDNT, BFLY, VREX
In The Past
Nano X Imaging's stock fell -94.4% during the 2022 Inflation Shock from a high on 1/27/2021. A -94.4% loss requires a 1698.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nano X Imaging (NNOX)
Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel digital MEMs semiconductor cathode. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Neve Ilan, Israel.
AI Analysis | Feedback
Nano X Imaging (NNOX) can be described with the following analogies:
NNOX is like a semiconductor company, similar to NVIDIA, but instead of GPUs for AI, they're developing a revolutionary digital 'chip' for X-ray generation that could power the next generation of medical imaging devices.
NNOX is building an ecosystem similar to Peloton or Ring, combining innovative imaging hardware (Nanox.ARC) with a cloud-based 'screening as a service' platform (Nanox.CLOUD) to make advanced X-ray diagnostics more accessible.
AI Analysis | Feedback
- Digital X-ray Source Technology: A novel digital MEMs semiconductor cathode-based X-ray source developed for the medical imaging industry.
- Nanox.ARC: A prototype medical imaging system that incorporates the company's novel digital X-ray source.
- Nanox.CLOUD: A companion cloud-based software platform designed to enable medical screening as a service.
AI Analysis | Feedback
Nano X Imaging (NNOX) Major Customers
Nano X Imaging (NNOX) operates primarily in a business-to-business (B2B) model, providing digital X-ray source technology, medical imaging systems, and cloud-based software to healthcare providers and medical imaging service companies. As a development-stage company, its commercialization strategy heavily relies on strategic partnerships and deployment agreements rather than traditional direct sales to a broad customer base.
One of its major partners and intended customers for the large-scale deployment of its Nanox.ARC medical imaging systems is:
- USARAD Holdings Inc. (and its affiliate, Medical Diagnostic Web) - This company is a provider of teleradiology and telemedicine services. It has entered into an agreement with Nano X Imaging for the deployment of Nanox.ARC systems in the United States. USARAD Holdings Inc. is not a public company.
Nano X Imaging is also pursuing deployment agreements and strategic collaborations with various entities, including healthcare ministries, large hospital groups, and distributors in multiple regions worldwide, to expand the reach of its technology.
AI Analysis | Feedback
- Sanmina Corporation (SANM)
- Foxconn Technology Group (TPE: 2317)
- Tower Semiconductor Ltd. (TSEM)
AI Analysis | Feedback
Erez Meltzer, Chief Executive Officer & Board Member
Mr. Meltzer assumed the role of CEO in late 2021, after serving on the Nano-X Imaging Board for two years. He brings over 35 years of leadership experience, having held executive positions across various global industries. His previous leadership roles include Chairman of the Board at Hadassah Medical Center in Israel for six years, and heading companies such as Gadot Chemicals & Shipping Group, Africa Israel, Netafim, and Creo Scitex.
Ran Daniel, Chief Financial Officer
Mr. Daniel has over 25 years of financial and business management expertise, including significant experience as a CFO in both rapidly growing and publicly traded companies. He is responsible for managing the financial and accounting functions of Nano-X Imaging.
Jim Dara, General Manager of Source & Services Division & Head of Nanox USA
Mr. Dara has held senior executive roles in multinational companies. Prior to joining Nano-X Imaging, he served as President of MyCharge, and before that, as VP of Business Development at Powermat and VP and interim CEO at Wellsense.
Tamar Aharon Cohen, EVP & Chief Marketing Officer
Ms. Aharon Cohen possesses over a decade of experience within global corporations. Her prior positions include serving as CEO at Tempo-Heineken Cyprus and as Division Manager and Marketing Manager at Tempo-Heineken Israel.
Ofir Koren, General Manager of ARC Division
Mr. Koren is an experienced technological leader. His previous roles include General Manager and VP R&D at ReWalk Robotics, General Manager of RuggedCom, and VP R&D of Alvarion, where he led the development of their WiMax mobile solution.
AI Analysis | Feedback
The key risks to Nano-X Imaging Ltd. (NNOX) are primarily centered around its financial viability, the successful commercialization and market adoption of its novel technology, and ongoing regulatory hurdles and technology validation.
- Financial Viability / High Cash Burn and Uncertainty of Profitability: As a development-stage company, Nano-X Imaging faces significant financial challenges, characterized by a high cash burn rate, persistent net losses, and negative gross profit margins. The company's financial health indicators raise concerns about its ability to achieve profitability and maintain sufficient cash reserves to fund ongoing operations and commercialization efforts, potentially leading to further shareholder dilution through capital raises.
- Commercialization and Market Adoption Challenges: Despite receiving some regulatory clearances, Nano-X Imaging has encountered difficulties in translating its innovative technology into significant commercial sales and widespread market adoption. This risk encompasses challenges in scaling up manufacturing and sales operations, navigating long sales cycles inherent in the healthcare sector, securing favorable reimbursement policies, and competing effectively against well-established players in the medical imaging industry.
- Regulatory Hurdles and Technology Validation: While Nano-X Imaging has achieved some FDA 510(k) clearances for its Nanox.ARC system and AI features, the company has experienced past regulatory delays and continues to face ongoing requirements for clearances for expanded indications and additional AI modules. The successful and timely completion of these regulatory processes, coupled with rigorous clinical validation of its novel digital X-ray source technology, remains critical for its ability to launch and generate revenue in key markets.
AI Analysis | Feedback
nullAI Analysis | Feedback
Nano X Imaging (NNOX) operates in the expansive medical imaging and health screening industries, addressing significant global markets with its innovative technologies.
For its core digital X-ray source technology and the Nanox.ARC medical imaging system, the estimated global addressable market is substantial. The global digital X-ray market is projected to be valued at approximately USD 15.7 billion in 2025 and is expected to grow to USD 36.0 billion by 2035.
Regarding Nanox.CLOUD, which offers cloud-based software for medical screening as a service, the global medical health screening market serves as its addressable market. This market was valued at around USD 28.09 billion in 2024 and is projected to reach approximately USD 48.07 billion by 2034.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Nano X Imaging (NNOX)
- Commercialization and Deployment of Nanox.ARC: Nano X Imaging is actively focusing on the global commercial rollout and deployment of its Nanox.ARC medical imaging system. The company anticipates deploying over 100 clinical, demo, and commercial units worldwide by the end of 2025. This expansion is supported by recent distribution agreements in key regions, including the southeastern United States and various European countries such as Serbia, Montenegro, Bosnia and Herzegovina, Greece, Romania, the Czech Republic, and France. Revenue generation from this driver will come from both the sale or leasing of the devices and a "Radiology-as-a-Service" (RaaS) model.
- Growth of AI Solutions (Nanox.AI) and Related Services: A significant driver of future revenue growth is the expansion and monetization of Nano X Imaging's artificial intelligence (AI) solutions. The company is transitioning from a pure hardware developer to a comprehensive imaging platform, with AI as a core component of its value proposition. The acquisition of VasoHealthcare IT in the third quarter of 2025 bolstered its AI and teleradiology segments, providing a robust infrastructure for integrating AI into healthcare facilities and creating new revenue streams. Nano X Imaging expects its AI business segment to reach quarterly EBITDA breakeven in 2026. Further, anticipated FDA 510(k) clearances for chest and full-body AI modules in the first half of 2026 are expected to significantly advance its AI strategy and U.S. market entry.
- Expansion of Radiology Services (Teleradiology via Nanox.MARKETPLACE): Teleradiology services, offered through the Nanox.MARKETPLACE, currently represent the primary revenue source for the company, accounting for approximately 91% of total revenues as of Q3 2025. Future growth is expected to stem from continued customer retention and an increased volume of reading services provided through this platform. The Nanox.MARKETPLACE connects medical facilities with remote radiology and cardiology experts, forming a recurring revenue model.
- Geographic Market Expansion and Strategic Partnerships: Nano X Imaging is actively pursuing a strategy of geographic expansion through strategic partnerships. The company is building a diverse network of regional distributors to accelerate the commercial introduction of its Nanox.ARC system and other solutions in new markets. Examples include distribution agreements in the U.S. Southeast and several European countries, which aim to expand access to cost-effective medical imaging solutions globally.
AI Analysis | Feedback
Share Repurchases
No significant share repurchase programs or executed buybacks have been reported by Nano-X Imaging in the last 3-5 years. The number of outstanding shares has consistently increased during this period, which is contrary to share repurchases.
Share Issuance
- In November 2025, Nano-X Imaging announced a registered direct offering to a single institutional investor, selling 3,826,530 ordinary shares at $3.92 per share, generating approximately $15 million in gross proceeds.
- The company's shares outstanding have shown a consistent increase over the last five years, growing from 38.02 million in 2020 to 64.32 million in 2025.
- As of the fourth quarter of 2024, Nano-X Imaging Ltd. had 64 million shares outstanding, which represented an increase of 10.4% from the preceding quarter.
Inbound Investments
- Nano-X Imaging raised approximately $15 million in gross proceeds through a registered direct offering of ordinary shares in November 2025.
- As of the third quarter of 2025, the company reported $55 million in cash and equivalents, with an additional $50 million recently raised to support commercialization and expansion efforts.
Outbound Investments
- In November 2025, Nano-X Imaging agreed to acquire VasoHealthcare IT Corp for a total consideration of up to $0.8 million, consisting of a $0.2 million cash payment at closing and up to $0.6 million in performance-based earnout payments. This acquisition aims to accelerate the deployment of Nanox.AI's solutions in U.S. healthcare facilities.
- In November 2021, Nano-X Imaging completed the acquisition of USARAD Holdings Inc. and Medical Diagnostics Web (MDW, LLC) for a total consideration of $30 million, comprising $21 million in Nanox shares and $9 million in cash. This was done to create an integrated, globally connected end-to-end radiology solution.
- In August 2021, the company announced an agreement to acquire Zebra Medical Vision Ltd. for an upfront payment of $100 million in Nanox shares, with potential for up to an additional $100 million in milestone-based payments, also in shares. This acquisition aimed to develop next-generation AI-enabled hardware and software devices.
Capital Expenditures
- Nano-X Imaging's capital expenditures were approximately $2.77 million in 2024, $3.30 million in 2023, and $7.17 million in 2022.
- In 2021, capital expenditures totaled approximately $23.16 million.
- These capital expenditures primarily focus on advancing the company's medical imaging technology, including the Nanox.ARC system and its AI solutions, supporting manufacturing scale-up, and commercial deployment.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Nano X Imaging Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NNOX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 37.62 |
| Mkt Cap | 3.0 |
| Rev LTM | 1,447 |
| Op Inc LTM | 77 |
| FCF LTM | 36 |
| FCF 3Y Avg | 47 |
| CFO LTM | 157 |
| CFO 3Y Avg | 156 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.2% |
| Rev Chg 3Y Avg | 7.6% |
| Rev Chg Q | 10.4% |
| QoQ Delta Rev Chg LTM | 2.7% |
| Op Mgn LTM | 6.2% |
| Op Mgn 3Y Avg | 6.1% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 5.8% |
| CFO/Rev 3Y Avg | 8.6% |
| FCF/Rev LTM | 1.3% |
| FCF/Rev 3Y Avg | 3.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.0 |
| P/S | 3.2 |
| P/EBIT | 3.7 |
| P/E | -4.9 |
| P/CFO | 15.9 |
| Total Yield | -4.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.9% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.8% |
| 3M Rtn | -8.6% |
| 6M Rtn | -5.0% |
| 12M Rtn | 6.5% |
| 3Y Rtn | -3.4% |
| 1M Excs Rtn | 1.2% |
| 3M Excs Rtn | -7.8% |
| 6M Excs Rtn | -5.2% |
| 12M Excs Rtn | -14.9% |
| 3Y Excs Rtn | -75.6% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Radiology services | 9 | 8 | 1 | ||
| Artificial Intelligence (AI) Solutions | 0 | 0 | 0 | ||
| Nanox. ARC | 0 | 0 | |||
| Total | 10 | 9 | 1 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Radiology services | -4 | -3 | -1 | ||
| Artificial Intelligence (AI) Solutions | -16 | -48 | -4 | ||
| Nanox. ARC | -42 | -67 | -57 | ||
| Total | -63 | -118 | -62 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Nanox. ARC | 131 | 148 | 196 | ||
| Artificial Intelligence (AI) Solutions | 66 | 75 | 136 | ||
| Radiology services | 22 | 31 | 32 | ||
| Single Segment | 236 | 12 | |||
| Total | 219 | 254 | 363 | 236 | 12 |
Price Behavior
Price Behavior
| Market Price | $2.59 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 08/21/2020 | |
| Distance from 52W High | -57.7% | |
| 50 Days | 200 Days | |
| DMA Price | $2.69 | $3.82 |
| DMA Trend | down | down |
| Distance from DMA | -3.6% | -32.2% |
| 3M | 1YR | |
| Volatility | 58.5% | 68.2% |
| Downside Capture | 347.69 | 265.56 |
| Upside Capture | 252.13 | 134.80 |
| Correlation (SPY) | 41.7% | 39.3% |
NNOX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.36 | 2.84 | 2.72 | 2.02 | 1.51 | 1.81 |
| Up Beta | 2.29 | 0.95 | 2.01 | 2.86 | 1.26 | 1.45 |
| Down Beta | 1.40 | 2.19 | 2.24 | 0.83 | 1.08 | 1.82 |
| Up Capture | 313% | 340% | 103% | 148% | 171% | 551% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 22 | 26 | 50 | 104 | 327 |
| Down Capture | 483% | 365% | 391% | 238% | 159% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 18 | 34 | 73 | 143 | 416 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNOX | |
|---|---|---|---|---|
| NNOX | -50.3% | 68.2% | -0.76 | - |
| Sector ETF (XLV) | 6.4% | 17.5% | 0.20 | 31.1% |
| Equity (SPY) | 22.5% | 18.9% | 0.94 | 39.4% |
| Gold (GLD) | 68.7% | 26.2% | 1.98 | 1.6% |
| Commodities (DBC) | 19.7% | 17.3% | 0.91 | 14.3% |
| Real Estate (VNQ) | 9.3% | 16.2% | 0.37 | 37.1% |
| Bitcoin (BTCUSD) | -9.2% | 44.2% | -0.09 | 33.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNOX | |
|---|---|---|---|---|
| NNOX | -41.8% | 90.2% | -0.22 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 22.7% |
| Equity (SPY) | 13.1% | 17.0% | 0.60 | 34.0% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | 3.1% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 4.4% |
| Real Estate (VNQ) | 4.9% | 18.8% | 0.16 | 26.8% |
| Bitcoin (BTCUSD) | 6.1% | 56.7% | 0.33 | 21.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNOX | |
|---|---|---|---|---|
| NNOX | -18.8% | 101.3% | 0.06 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 18.8% |
| Equity (SPY) | 14.7% | 17.9% | 0.70 | 29.3% |
| Gold (GLD) | 14.4% | 15.6% | 0.76 | 2.8% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 4.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 23.1% |
| Bitcoin (BTCUSD) | 67.9% | 66.8% | 1.07 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/20/2025 | 6-K |
| 06/30/2025 | 08/12/2025 | 6-K |
| 03/31/2025 | 05/22/2025 | 6-K |
| 12/31/2024 | 04/09/2025 | 20-F |
| 09/30/2024 | 11/21/2024 | 6-K |
| 06/30/2024 | 08/20/2024 | 6-K |
| 03/31/2024 | 05/28/2024 | 6-K |
| 12/31/2023 | 04/22/2024 | 20-F |
| 09/30/2023 | 11/28/2023 | 6-K |
| 06/30/2023 | 08/17/2023 | 6-K |
| 03/31/2023 | 05/22/2023 | 6-K |
| 12/31/2022 | 05/01/2023 | 20-F |
| 09/30/2022 | 11/10/2022 | 6-K |
| 06/30/2022 | 08/16/2022 | 6-K |
| 03/31/2022 | 05/23/2022 | 6-K |
| 12/31/2021 | 05/02/2022 | 20-F |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel, Ran | CFO | Direct | Buy | 9052025 | 3.65 | 1,000 | 3,650 | 25,368 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.